explore -WSS

explore

author：leisure time 2025-10-01 21:48:29 - browse：61

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： CRISPR pioneers react to Casgevy, first gene

WSS

Affordable Connectivity Program vital to health care, experts say

Wegovy, Zepbound and weight loss drugs that preserve muscle

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Vir antibody drug aimed at influenza A fails in clinical trial

Tesla recalling nearly 16,000 of its 2021

Indian pharmaceutical industry in denial over drug

explore

explore

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

David Sabatini, ex

Heart attack and stroke risk calculators need revising

Texas Department of Public Safety speaks out on migrant abuse allegations

State Dept. review finds Biden bears some blame for Afghanistan failures

Driven by the pandemic, applicants flood public health schools

Tori Bowie and the unacceptable rates of Black maternal death

7 more heat

Walensky prepares to leave CDC — and Congress — behind

Does good food count as health care? Study aims to find out

knowledge

CRISPR pioneers react to Casgevy, first gene

Readout LOUD podcast: A CRISPR milestone, biotech mixology

PBM reforms clear House panel

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Poor hospice wound care hurts patients and families

A daunting task: navigating dual Medicare, Medicaid eligibility

hotspot

focus

explore

entertainment